

Selectively inhibiting PKM2 starves cancer cells

January 23 2012

Crippling a protein that allows cancer cells to grow when oxygen is scarce causes tumors to regress, according to a study published online on January 23 in the *Journal of Experimental Medicine*.

An enzyme called PKM2 (M2 isoform of pyruvate kinase) is ramped up in cancer cells, allowing them to generate energy in the harsh, low-oxygen environment found within tumors.

Michael Goldberg and Phillip Sharp at the Massachusetts Institute of Technology now find that inhibiting PKM2 kills <u>cancer cells</u> by starving them of energy but leaves normal cells unscathed. Crippling PKM2 caused established tumors in mice to melt away. If these results hold true in humans, this strategy could prove effective against a wide spectrum of cancers with minimal side effects.

More information: Goldberg, M.S., and P.A. Sharp. 2012. J. Exp. Med. doi:10.1084/jem.20111487

Provided by Rockefeller University

Citation: Selectively inhibiting PKM2 starves cancer cells (2012, January 23) retrieved 19

November 2023 from

https://medicalxpress.com/news/2012-01-inhibiting-pkm2-starves-cancer-cells.html



This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.